Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Finanical ReportsHKG: 2359

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit…

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors
CancerClinical trial approval / initiation

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India
CAR-TNovatim Immune Therapeutics

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis
China Medical SystemClinical trial results

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition
ETR: MRKMerck

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition

Show More